 |
|
Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors
Anthony T. P. Chan, Sydney C. W. Tang
Kidney Res Clin Pract. 2022;41(6):682-698. Published online 2022 Jul 19 DOI: https://doi.org/10.23876/j.krcp.21.285
|
|
Citations to this article as recorded by
 Blood pressure control in diabetic kidney disease: a post-hoc analysis of the FANTASTIC trial
Cheol Ho Park, Soon Jun Hong, Sung Gyun Kim, Seok Joon Shin, Dong Ki Kim, Jung Pyo Lee, Sang Youb Han, Sangho Lee, Jong Chul Won, Young Sun Kang, Jongha Park, Byoung-Geun Han, Ki-Ryang Na, Kyu Yeon Hur, Yong-Jin Kim, Sungha Park, Tae-Hyun Yoo
Clinical Hypertension.2024;[Epub] CrossRef Obesity-related hypertension and chronic kidney disease: from evaluation to management
Mi-Hyang Jung, Sang-Hyun Ihm
Kidney Research and Clinical Practice.2023; 42(4): 431. CrossRef Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis
Eun Sil Koh, Gheun-Ho Kim, Sungjin Chung
Endocrinology and Metabolism.2023; 38(4): 359. CrossRef Molecular Mechanistic Pathways Targeted by Natural Compounds in the Prevention and Treatment of Diabetic Kidney Disease
Kaixuan Zhou, Xue Zi, Jiayu Song, Qiulu Zhao, Jia Liu, Huiwei Bao, Lijing Li
Molecules.2022; 27(19): 6221. CrossRef
|